Epigenetic Drugs & Diagnostics Market
Upcoming research reports. Delivery timeline: 4 weeks
The epigenetic drugs and diagnostics market includes treatments and diagnostic tools that target changes in gene expression without altering DNA sequences. This market covers DNA methylation inhibitors (e.g., azacitidine, decitabine), histone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin), and other emerging therapies used in cancer, neurological disorders, and autoimmune diseases. Increasing R&D investments, a focus on precision medicine, and growing funding are key factors driving market growth. Advances in next-generation sequencing (NGS) and biomarker-based diagnostics are also improving disease detection and personalized treatment approaches. There are opportunities in developing new epigenetic drugs that target enzymes like SETD2 (EZH2), LSD1, and BET proteins, expanding treatment options beyond cancer. However, market growth is limited by the off-target effects of epigenetic drugs, as their complex mechanisms are not yet fully understood. Despite these challenges, ongoing research and technological progress continue to advance this field.
Epigenetic Drugs & Diagnostics Market- Global Forecast to 2030
Global Epigenetics Drugs & Diagnostics Market Dynamics
Driver: Increasing research & investments supported by rising focus on precision medicines to drive growth
Increasing investments in epigenetics research, driven by the demand for personalized medicine, are key factors supporting the growth of the epigenetic drugs and diagnostics market. Initiatives such as the November 2024, partnership of Oxford Nanopore Technologies with UK Biobank aim to improve disease detection and treatment through large-scale epigenomic mapping. This project, sequencing 50,000 participant samples, will help identify key methylation markers linked to various diseases. Similarly, in January 2025, researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences explored a potential epigenetic therapy for colorectal cancer by targeting the UHRF1 protein using mRNA-based lipid nanoparticle technology.
Moreover, companies like Chroma Medicine are also advancing the field, securing USD 135 million in Series B financing to develop single-dose epigenetic editing therapies. Additionally, studies on DNA methyltransferase inhibitors (DNMTis) and EZH2 inhibitors (EZH2is) suggest that combining these therapies can improve treatment response in solid tumors by modifying the epigenomic landscape. Institutions like the University of Texas MD Anderson Cancer Center publish a high volume of studies relating to epigenetic therapies. Key research areas include drug resistance, immunotherapy, and combination therapies, emphasizing the need for optimized treatment strategies. With ongoing funding, research advancements, and new therapeutic approaches, the epigenetics market is expected to grow further.
Challenge: Limited understanding of epigenetic mechanism and off-target effects of epigenetic drugs, a major challenge to adoption
A key challenge in the epigenetic drugs and diagnostics market is the limited understanding of epigenetic mechanisms. There are gaps in knowledge about DNA and RNA modifications, reader domains, and protein interactions, making it difficult to identify effective drug targets. More research is needed to understand how these modifications influence diseases and treatment responses. Another challenge is the off-target effects of epigenetic drugs. Many of these drugs lack specificity and affect multiple enzymes, which can cause unintended side effects. To improve safety and effectiveness, precise drug delivery is essential. Advanced delivery systems like lipid nanoparticles are being explored to enhance targeting. Overcoming these challenges will require further research, better drug design, and improved delivery technologies.
Recent Developments in the Epigenetic Drugs and Diagnostics Market:
In January 2025, Tune Therapeutics raised USD 175 million in a Series B funding round to advance epigenetic editing therapies, which modify gene expression without DNA alteration. The therapy aims to silence viral DNA, preventing further virus production.
In January 2024, MoonWalk Biosciences, raised USD 57 million in seed and Series A funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. The funding will support the advancement of Moonwalk’s epigenetic profiling and engineering platform and its therapeutic pipeline. The company aims to develop precision epigenetic medicines by targeting the epigenetic code.
In January 2024, Novo Nordisk entered into a partnership with Omega Therapeutics to develop novel treatments for cardiometabolic diseases. Omega’s epigenomic controller technology will enhance thermogenesis and metabolic activity for obesity management.
The epigenetic drugs and diagnostics market includes treatments and diagnostic tools that target changes in gene expression without altering DNA sequences. This market covers DNA methylation inhibitors (e.g., azacitidine, decitabine), histone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin), and other emerging therapies used in cancer, neurological disorders, and autoimmune diseases. Increasing R&D investments, a focus on precision medicine, and growing funding are key factors driving market growth. Advances in next-generation sequencing (NGS) and biomarker-based diagnostics are also improving disease detection and personalized treatment approaches. There are opportunities in developing new epigenetic drugs that target enzymes like SETD2 (EZH2), LSD1, and BET proteins, expanding treatment options beyond cancer. However, market growth is limited by the off-target effects of epigenetic drugs, as their complex mechanisms are not yet fully understood. Despite these challenges, ongoing research and technological progress continue to advance this field.
Epigenetic Drugs & Diagnostics Market- Global Forecast to 2030
Global Epigenetics Drugs & Diagnostics Market Dynamics
Driver: Increasing research & investments supported by rising focus on precision medicines to drive growth
Increasing investments in epigenetics research, driven by the demand for personalized medicine, are key factors supporting the growth of the epigenetic drugs and diagnostics market. Initiatives such as the November 2024, partnership of Oxford Nanopore Technologies with UK Biobank aim to improve disease detection and treatment through large-scale epigenomic mapping. This project, sequencing 50,000 participant samples, will help identify key methylation markers linked to various diseases. Similarly, in January 2025, researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences explored a potential epigenetic therapy for colorectal cancer by targeting the UHRF1 protein using mRNA-based lipid nanoparticle technology.
Moreover, companies like Chroma Medicine are also advancing the field, securing USD 135 million in Series B financing to develop single-dose epigenetic editing therapies. Additionally, studies on DNA methyltransferase inhibitors (DNMTis) and EZH2 inhibitors (EZH2is) suggest that combining these therapies can improve treatment response in solid tumors by modifying the epigenomic landscape. Institutions like the University of Texas MD Anderson Cancer Center publish a high volume of studies relating to epigenetic therapies. Key research areas include drug resistance, immunotherapy, and combination therapies, emphasizing the need for optimized treatment strategies. With ongoing funding, research advancements, and new therapeutic approaches, the epigenetics market is expected to grow further.
Challenge: Limited understanding of epigenetic mechanism and off-target effects of epigenetic drugs, a major challenge to adoption
A key challenge in the epigenetic drugs and diagnostics market is the limited understanding of epigenetic mechanisms. There are gaps in knowledge about DNA and RNA modifications, reader domains, and protein interactions, making it difficult to identify effective drug targets. More research is needed to understand how these modifications influence diseases and treatment responses. Another challenge is the off-target effects of epigenetic drugs. Many of these drugs lack specificity and affect multiple enzymes, which can cause unintended side effects. To improve safety and effectiveness, precise drug delivery is essential. Advanced delivery systems like lipid nanoparticles are being explored to enhance targeting. Overcoming these challenges will require further research, better drug design, and improved delivery technologies.
Recent Developments in the Epigenetic Drugs and Diagnostics Market:
In January 2025, Tune Therapeutics raised USD 175 million in a Series B funding round to advance epigenetic editing therapies, which modify gene expression without DNA alteration. The therapy aims to silence viral DNA, preventing further virus production.
In January 2024, MoonWalk Biosciences, raised USD 57 million in seed and Series A funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. The funding will support the advancement of Moonwalk’s epigenetic profiling and engineering platform and its therapeutic pipeline. The company aims to develop precision epigenetic medicines by targeting the epigenetic code.
In January 2024, Novo Nordisk entered into a partnership with Omega Therapeutics to develop novel treatments for cardiometabolic diseases. Omega’s epigenomic controller technology will enhance thermogenesis and metabolic activity for obesity management.
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.2 COMPLIMENTARY TECHNOLOGIES
5.7.3 ADJACENT TECHNOLOGIES
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.9.2 REGULATORY FRAMEWORK
5.10 PRICING ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2025-26
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.12.2 BUYING CRITERIA FOR END USERS
5.13 PATENT ANALYSIS
5.14 INVESTMENT AND FUNDING ACTIVITIES
5.15 IMPACT OF AI/GENERATIVE AI ON EPIGENETIC DRUGS & DIAGNOSTICS MARKET
6 EPIGENETIC DRUGS MARKET, BY DRUG CLASS
6.1 INTRODUCTION
6.2 DNA METHYLATION INHIBITORS
6.3 HISTONE MODIFICATION ENZYME INHIBITORS
6.4 ISOCITRATE DEHYDROGENASE (IDH) INHIBITORS
6.5 OTHER DRUG CLASSES
7 EPIGENETIC DRUGS MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 HEMATOLOGIC MALIGNANCIES
7.2.2 SOLID TUMORS
7.2.3 OTHER CANCERS
7.3 NON-ONCOLOGY
7.3.1 NEUROLOGICAL DISORDER
7.3.2 AUTOIMMUNE DISEASES
7.3.3 INFECTIOUS DISEASE
7.3.4 OTHER DISEASES
8 EPIGENETIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 ORAL
8.3 INTRAVENOUS
9 EPIGENETIC DIAGNOSTICS MARKET, BY TEST TYPE
9.1 INTRODUCTION
9.2 PCR ASSAYS
9.3 NGS ASSAYS
9.4 OTHERS
10 EPIGENETIC DIAGNOSTICS MARKET, BY PRODUCT TYPE
10.1 INTRODUCTION
10.2 REAGENTS & KITS
10.3 INSTRUMENTS
10.4 SOFTWARE & BIOINFORMATICS TOOLS
11 EPIGENETIC DRUGS & DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITAL
11.3 SPECIALTY CLINICS
11.4 RESEARCH INSTITUTES
12 EPIGENETIC DRUGS & DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.3 CANADA
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.3 UK
12.3.4 FRANCE
12.3.5 ITALY
12.3.6 SPAIN
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.3 JAPAN
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.5 SOUTH KOREA
12.4.6 REST OF APAC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.1 BRAZIL
12.5.2 MEXICO
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.7 AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024
13.3 REVENUE SHARE ANALYSIS, 2022-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 EPIGENETIC DRUGS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.6 COMPANY FOOTPRINT, KEY PLAYERS, 2024
13.6.1 COMPANY FOOTPRINT
13.6.2 DRUG CLASS FOOTPRINT
13.6.3 INDICATION FOOTPRINT
13.6 COMPANY EVALUATION MATRIX, PIPELINE COMPANIES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.6.5.1 DETAILED LIST OF PIPELINE COMPANIES
13.6.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
13.7 EPIGENETIC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.8 COMPANY FOOTPRINT, KEY PLAYERS, 2024
13.8.1 COMPANY FOOTPRINT
13.8.2 REGIONAL FOOTPRINT
13.8.3 TEST TYPE FOOTPRINT
13.8 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.8.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
13.8.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
13.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
13.10 VENDOR VALUATION AND FINANCIAL METRICS OF THE EPIGENETIC DRUGS MARKET
13.11 VENDOR VALUATION AND FINANCIAL METRICS OF THE EPIGENETIC DIAGNOSTICS MARKET
13.12 COMPETITIVE SCENARIO AND TRENDS
13.12.1 PRODUCT APPROVALS/ LAUNCHES
13.12.2 DEALS
13.12.3 OTHER DEVELOPMENTS
14 COMPANY PROFILES
14.1 KEY PLAYERS (APPROVED DRUGS)
14.1.1 BMS
14.1.2 AstraZenca
14.1.3 Ispen
14.1.4 Merck & Co.
14.1.5 Otsuka Pharmaceutical Co., Ltd
14.1.6 ITF Therapeutics LLC
14.1.7 Acrotech Biopharma
14.1.8 Chipscreen Biosciences
14.1.9 Secura Bio
14.1.10 Servier
14.1.11 Rigel
14.2 KEY PLAYERS (DIAGNOSTICS)
14.2.1 ABBOTT
14.2.2 THERMO FISHER SCIENTIFIC INC.
14.2.3 F. HOFFMANN-LA ROCHE LTD
14.2.4 QIAGEN
14.2.5 PROMEGA
14.2.6 TAKARA
14.2.7 NEW ENGLAND BIOLABS
14.2.8 AMOYDX
14.2.9 Quir?nsalud
14.3 OTHER PLAYERS (PIPELINE)
14.3.1 Eli Lilly and Company
14.3.2 Novartis
14.3.3 Novo Nordisk
14.3.4 Omega Therapeutics
14.3.5 Zenith Epigenetics.
14.3.6 nChromaBio
14.3.7 STORM Therapeutics LTD
14.3.8 K36 Therapeutics
14.3.9 Epic Bio
14.3.10 Inherent Biosciences
14.3.11 Evopoint Biosciences Co., Ltd
14.3.12 Epizyme, Inc.
14.3.13 Pfizer
14.3.14 Bayer
Note: Above list is an indicative list of companies. Details on business overview, financial information, product portfolio, recent developments, and MarketsandMarkets view (for top players) will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
Note: The given segmentation is tentative and subject to change during the course of research.
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.2 COMPLIMENTARY TECHNOLOGIES
5.7.3 ADJACENT TECHNOLOGIES
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.9.2 REGULATORY FRAMEWORK
5.10 PRICING ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2025-26
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.12.2 BUYING CRITERIA FOR END USERS
5.13 PATENT ANALYSIS
5.14 INVESTMENT AND FUNDING ACTIVITIES
5.15 IMPACT OF AI/GENERATIVE AI ON EPIGENETIC DRUGS & DIAGNOSTICS MARKET
6 EPIGENETIC DRUGS MARKET, BY DRUG CLASS
6.1 INTRODUCTION
6.2 DNA METHYLATION INHIBITORS
6.3 HISTONE MODIFICATION ENZYME INHIBITORS
6.4 ISOCITRATE DEHYDROGENASE (IDH) INHIBITORS
6.5 OTHER DRUG CLASSES
7 EPIGENETIC DRUGS MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 HEMATOLOGIC MALIGNANCIES
7.2.2 SOLID TUMORS
7.2.3 OTHER CANCERS
7.3 NON-ONCOLOGY
7.3.1 NEUROLOGICAL DISORDER
7.3.2 AUTOIMMUNE DISEASES
7.3.3 INFECTIOUS DISEASE
7.3.4 OTHER DISEASES
8 EPIGENETIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 ORAL
8.3 INTRAVENOUS
9 EPIGENETIC DIAGNOSTICS MARKET, BY TEST TYPE
9.1 INTRODUCTION
9.2 PCR ASSAYS
9.3 NGS ASSAYS
9.4 OTHERS
10 EPIGENETIC DIAGNOSTICS MARKET, BY PRODUCT TYPE
10.1 INTRODUCTION
10.2 REAGENTS & KITS
10.3 INSTRUMENTS
10.4 SOFTWARE & BIOINFORMATICS TOOLS
11 EPIGENETIC DRUGS & DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITAL
11.3 SPECIALTY CLINICS
11.4 RESEARCH INSTITUTES
12 EPIGENETIC DRUGS & DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.3 CANADA
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.3 UK
12.3.4 FRANCE
12.3.5 ITALY
12.3.6 SPAIN
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.3 JAPAN
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.5 SOUTH KOREA
12.4.6 REST OF APAC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.1 BRAZIL
12.5.2 MEXICO
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.7 AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024
13.3 REVENUE SHARE ANALYSIS, 2022-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 EPIGENETIC DRUGS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.6 COMPANY FOOTPRINT, KEY PLAYERS, 2024
13.6.1 COMPANY FOOTPRINT
13.6.2 DRUG CLASS FOOTPRINT
13.6.3 INDICATION FOOTPRINT
13.6 COMPANY EVALUATION MATRIX, PIPELINE COMPANIES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.6.5.1 DETAILED LIST OF PIPELINE COMPANIES
13.6.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
13.7 EPIGENETIC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.8 COMPANY FOOTPRINT, KEY PLAYERS, 2024
13.8.1 COMPANY FOOTPRINT
13.8.2 REGIONAL FOOTPRINT
13.8.3 TEST TYPE FOOTPRINT
13.8 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.8.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
13.8.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
13.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
13.10 VENDOR VALUATION AND FINANCIAL METRICS OF THE EPIGENETIC DRUGS MARKET
13.11 VENDOR VALUATION AND FINANCIAL METRICS OF THE EPIGENETIC DIAGNOSTICS MARKET
13.12 COMPETITIVE SCENARIO AND TRENDS
13.12.1 PRODUCT APPROVALS/ LAUNCHES
13.12.2 DEALS
13.12.3 OTHER DEVELOPMENTS
14 COMPANY PROFILES
14.1 KEY PLAYERS (APPROVED DRUGS)
14.1.1 BMS
14.1.2 AstraZenca
14.1.3 Ispen
14.1.4 Merck & Co.
14.1.5 Otsuka Pharmaceutical Co., Ltd
14.1.6 ITF Therapeutics LLC
14.1.7 Acrotech Biopharma
14.1.8 Chipscreen Biosciences
14.1.9 Secura Bio
14.1.10 Servier
14.1.11 Rigel
14.2 KEY PLAYERS (DIAGNOSTICS)
14.2.1 ABBOTT
14.2.2 THERMO FISHER SCIENTIFIC INC.
14.2.3 F. HOFFMANN-LA ROCHE LTD
14.2.4 QIAGEN
14.2.5 PROMEGA
14.2.6 TAKARA
14.2.7 NEW ENGLAND BIOLABS
14.2.8 AMOYDX
14.2.9 Quir?nsalud
14.3 OTHER PLAYERS (PIPELINE)
14.3.1 Eli Lilly and Company
14.3.2 Novartis
14.3.3 Novo Nordisk
14.3.4 Omega Therapeutics
14.3.5 Zenith Epigenetics.
14.3.6 nChromaBio
14.3.7 STORM Therapeutics LTD
14.3.8 K36 Therapeutics
14.3.9 Epic Bio
14.3.10 Inherent Biosciences
14.3.11 Evopoint Biosciences Co., Ltd
14.3.12 Epizyme, Inc.
14.3.13 Pfizer
14.3.14 Bayer
Note: Above list is an indicative list of companies. Details on business overview, financial information, product portfolio, recent developments, and MarketsandMarkets view (for top players) will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
Note: The given segmentation is tentative and subject to change during the course of research.
